Graeme Smith, CSO and Helen Robinson, VP Biology attending the 5th Digital DDR, ATR, & PARP Summit – 25/26 January 2022 25 January 2022 | Conferences
Listen to our CEO and CSO talk at the Northland Synthetic Lethality Conference – Nov 17 2021 2 December 2021 | Conferences
èßäAV³ÉÈË Appoints Nora Brennan to Board of Directors and Audit Committee Chair 16 November 2021 | Press release
èßäAV³ÉÈË Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215 28 September 2021 | Press release
More exciting press coverage following $153 Million financing – Series C 27 August 2021 | Media coverage
èßäAV³ÉÈË Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X 27 July 2021 | Press release
Exciting press coverage following our Polθ (Pol-theta) press release – Nature Communications 1 July 2021 | Media coverage
èßäAV³ÉÈË Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications 17 June 2021 | Press release
èßäAV³ÉÈË Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies 7 April 2021 | Press release